Successful treatment of non-small cell lung cancer with radiation therapy requires that the
physicians determine exactly where the tumor is in your body and protect your normal tissue.
This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission
Tomography (FDG-PET) and Ventilation/Perfusion Single Photon Emission Computerized Tomography
(V/Q SPECT), before treatment and then again during treatment to see if it helps predict how
well the treatment works for your cancer and how well your lung functions during treatment. A
Computerized Tomography (CT) will also be performed along with both of these procedures to
help the researchers see clearly where your cancer or your healthy lung is located.
The researchers are also doing blood tests in this study to look for markers in your blood
and to see if it helps them in determining your risk of developing side effects from
radiation to the lungs. The researchers hope that this study will help them in the future to
design radiation treatment plans that provide the best treatment for each individual patient.
Lung cancer is the leading cause of cancer deaths in the United States, of which 80% are lung
cancer (NSCLC, including squamous cell lung cancer, and small cell lung cancer). Although
surgery provides the best chance of cure, the majority of lung cancer require radiation for
treatment. The current radiation recommendation, using modern techniques and a uniform
radiation dose, generates an overall cure rate of less than 10-15%, and moderate toxicity in
10-30% of treated patients. Who can be cured and who will develop side effects? Computed
tomography (CT) provides a useful tool to monitor, but a limited power to predict both tumor
control and lung toxicity. Using [18F] fluorodeoxyglucose positron emission tomography
(FDG-PET) and ventilation/perfusion single photon emission computed tomography (V/Q SPECT),
we have recently shown changes in tumor activity and regional lung function during the course
of radiation, which may be associated with long-term outcome. The general strategy of this
project is to perform functional image and blood test during the course of radiation and
correlate them with long-term outcomes. By completing this study, we expect to generate
predictive models better than CT-based ones for both tumor control and lung toxicity.
- Histologically confirmed Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer
(SCLC) clinically diagnosed providing that FDG-PET is positive.
- Stage I to III lung cancer requiring definitive irradiation with or without
- Patients with a locoregional tumor recurrence following surgery will be eligible
provided they meet other eligibility criteria.
- Patients must be 18 years of age or older.
- Female patients with reproductive capability must be willing to use effective
- Patients must sign an informed consent form for study.
- Malignant pleural or pericardial effusion.
- Patients with diabetes mellitus, with uncontrolled fasting blood glucose level (above
- Inability to lie flat for the duration of PET/CT and V/Q SPECT (approximately 45
minutes for each study)
- Prisoners are excluded from this study.